Thomas Hanke
Directeur Technique/Scientifique/R&D chez TeGenero AG
Profil
Thomas Hanke is currently a Director at TeGenero AG, Dark Blue Therapeutics Ltd., and Autobahn Labs, Inc. He has an undergraduate degree from Wuerzburg Schweinfurt University of Applied Sciences and a doctorate degree from the same institution, which he received in 1995.
Postes actifs de Thomas Hanke
| Sociétés | Poste | Début |
|---|---|---|
TeGenero AG
 TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany. | Directeur Technique/Scientifique/R&D | 01/06/2000 |
Dark Blue Therapeutics Ltd.
 Dark Blue Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Dark Blue Therapeutics Ltd. operates as a biotechnology firm. The company was founded in June 4, 2020 an is headquartered in Oxford, the United Kingdom. | Directeur/Membre du Conseil | 24/07/2020 |
Autobahn Labs, Inc.
 Autobahn Labs, Inc. Medical/Nursing ServicesHealth Services Autobahn Labs, Inc. is a virtual incubator that partners with research institutions to accelerate the advancement of early-stage drug discovery and development. The company is based in Palo Alto, CA. The organization invests intellectual, financial, and physical capital to efficiently move projects from feasibility to novel drug candidates. Autobahn Labs was created by Samsara Biocapital, Evotec, and KCK Ltd. | Directeur/Membre du Conseil | - |
Formation de Thomas Hanke
| Wuerzburg Schweinfurt University of Applied Sciences | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
TeGenero AG
TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany. | Health Technology |
Dark Blue Therapeutics Ltd.
Dark Blue Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Dark Blue Therapeutics Ltd. operates as a biotechnology firm. The company was founded in June 4, 2020 an is headquartered in Oxford, the United Kingdom. | Health Technology |
Autobahn Labs, Inc.
Autobahn Labs, Inc. Medical/Nursing ServicesHealth Services Autobahn Labs, Inc. is a virtual incubator that partners with research institutions to accelerate the advancement of early-stage drug discovery and development. The company is based in Palo Alto, CA. The organization invests intellectual, financial, and physical capital to efficiently move projects from feasibility to novel drug candidates. Autobahn Labs was created by Samsara Biocapital, Evotec, and KCK Ltd. | Health Services |